| Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value N Olchanski, RN Hansen, E Pope, B D’Cruz, J Fergie, M Goldstein, ... Open Forum Infectious Diseases 5 (3), ofy031, 2018 | 83 | 2018 |
| The influence of time horizon on results of cost-effectiveness analyses DD Kim, CL Wilkinson, EF Pope, JD Chambers, JT Cohen, PJ Neumann Expert review of pharmacoeconomics & outcomes research 17 (6), 615-623, 2017 | 76 | 2017 |
| Specialty drug coverage varies across commercial health plans in the US JD Chambers, DD Kim, EF Pope, JS Graff, CL Wilkinson, PJ Neumann Health Affairs 37 (7), 1041-1047, 2018 | 63 | 2018 |
| The association between COVID-19 mortality and the county-level partisan divide in the United States: study examines the association between COVID-19 mortality and county-level … NJ Sehgal, D Yue, E Pope, RH Wang, DH Roby Health Affairs 41 (6), 853-863, 2022 | 52 | 2022 |
| Comorbidity type and health care costs in type 2 diabetes: a retrospective claims database analysis PJ Lin, E Pope, FL Zhou Diabetes Therapy 9 (5), 1907-1918, 2018 | 47 | 2018 |
| Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures PJ Neumann, JE Anderson, AD Panzer, EF Pope, BN D'Cruz, DD Kim, ... Gates open research 2, 2018 | 43 | 2018 |
| Little consistency in evidence cited by commercial plans for specialty drug coverage JD Chambers, AD Panzer, EF Pope, JS Graff, PJ Neumann Health Affairs 38 (11), 1882-1886, 2019 | 18 | 2019 |
| Discrepancies between FDA-required labeling and evidence that payers cite in drug coverage policies JD Chambers, EF Pope, CL Wilkinson, PJ Neumann Journal of Managed Care & Specialty Pharmacy 24 (12), 1240-1246, 2018 | 6 | 2018 |
| Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. Gates Open Res. 2018; 2: 5 PJ Neumann, JE Anderson, AD Panzer, EF Pope, BN D’Cruz, DD Kim, ... | 5 | 2018 |
| Cures Act, FDA draft guidance suggest flexibility on communication of real-world drug impacts, though questions remain PJ Neumann, E Pope Health Affairs Forefront, 2017 | 5 | 2017 |
| The Role of Physician Networks and Receipt of Opioid-Related Payments E Pope, N Sehgal Journal of General Internal Medicine, 2022 | 4 | 2022 |
| A comparison of coverage restrictions for biopharmaceuticals and medical procedures J Chambers, E Pope, K Bungay, J Cohen, M Ciarametaro, R Dubois, ... Value in Health 21 (4), 400-406, 2018 | 4 | 2018 |
| Knowledge, practice and attitudes regarding substance use disorder treatment and harm reduction strategies among pharmacists: a scoping review protocol E Pope, M McCullough, JG Smith, B Kim BMJ open 14 (2), e080338, 2024 | 1 | 2024 |
| Effects and Trends in Opioid-Related Promotional Payments Between 2014 and 2019: a Panel Data Analysis Among Prescribers in Medicare Part D E Pope, N Sehgal Journal of General Internal Medicine 37 (13), 3509-3511, 2022 | 1 | 2022 |
| The growth of cost-effectiveness analyses in Asia PJ Neumann, BN D'Cruz, JG Emerson, AD Panzer, JE Anderson, E Pope, ... Value in Health 21, S56, 2018 | 1 | 2018 |
| TRENDS IN UTILITY ELICITATION METHODS: DO ANALYSES ADHERE TO RECOMMENDATIONS? EF Pope, T Lavelle Value in Health 20 (5), A47-A47, 2017 | 1 | 2017 |
| Variation de la prévalence de l’hypertension artérielle dans les zones de Place Cazeau et de Delmas et analyse du mode d’expression utilisé RR Jean-Charles, O Diallo, E Pope | 1 | 2015 |
| Time-Motion Analysis of External Facilitation for Sustainably Implementing the Collaborative Chronic Care Model in General Mental Health Clinics B Kim, R Raciborski, J Sullivan, K Stolzmann, S Connolly, E Richardson, ... 2024 Annual Research Meeting, 2024 | | 2024 |
| Protocol: Knowledge, practice and attitudes regarding substance use disorder treatment and harm reduction strategies among pharmacists: a scoping review protocol E Pope, M McCullough, JG Smith, B Kim BMJ Open 14 (2), 2024 | | 2024 |
| Characterizing industry payments to US teaching hospitals and affiliated physicians: a cross-sectional analysis of the Open Payments datasets from 2016 to 2022 E Pope, N Sehgal Health Affairs Scholar 1 (2), qxad031, 2023 | | 2023 |
